Early detection of occult atrial fibrillation and stroke prevention

Heart

Volumn 101, Issue 14, 2015, Pages 1097-1102

  Keach, Joseph Walker ^a   Bradley, Steven M ^a,b   Turakhia, Mintu P ^c,d   Maddox, Thomas M ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Veterans Affairs Eastern Colorado Health Care System   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; ANTICOAGULANT AGENT; BIOLOGICAL MARKER;

AGE; ATRIAL FIBRILLATION; BLEEDING; BLOOD PRESSURE MONITOR; BODY HEIGHT; BODY WEIGHT; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPH; ETHNICITY; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOLTER MONITOR; HUMAN; IMPLANTABLE CARDIAC MONITOR; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; MEDICAL HISTORY; MOBILE PHONE; P WAVE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RR INTERVAL; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TREATMENT WITHDRAWAL; BLOOD; CARDIOVASCULAR SYSTEM EXAMINATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; RISK FACTOR; STANDARDS; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOMARKERS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84934268899     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-307588     Document Type: Review

References (50)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292.
2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
3. Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005;112:307-13.
4. Quirino G, Giammaria M, Corbucci G, et al. Diagnosis of paroxysmal atrial fibrillation in patients with implanted pacemakers: relationship to symptoms and other variables. Pacing Clin Electrophysiol 2009;32:91-8.
5. Silberbauer J, Veasey RA, Cheek E, et al. Electrophysiological characteristics associated with symptoms in pacemaker patients with paroxysmal atrial fibrillation. J Interv Card Electrophysiol 2009;26:31-40.
6. Rizos T, Rasch C, Jenetzky E, et al. Detection of paroxysmal atrial fibrillation in acute stroke patients. Cerebrovasc Dis 2010;30:410-17.
7. Seet RC, Friedman PA, Rabinstein AA. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 2011;124:477-86.
8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
9. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968.
10. Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
11. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383.
12. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med 2014;127:95.e11-17.
13. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol 2013;112:520-4.
14. Tarakji KG, Wazni OM, Callahan T, et al. Using a novel wireless system in monitoring patients after the atrial fibrillation ablation procedure: the iTransmit study. Heart Rhythm 2015;12:554-9.
15. Marazzi G, Iellamo F, Volterrani M, et al. Comparison of Microlife BP A200 Plus and Omron M6 blood pressure monitors to detect atrial fibrillation in hypertensive patients. Adv Ther 2012;29:64-70.
16. Samol A, Masin M, Gellner R, et al. Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 2013;15:657-62.
17. Parry SW, Matthews IG. Implantable loop recorders in the investigation of unexplained syncope: a state of the art review. Heart 2010;96:1611-16.
18. Healey J. Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patient With Cardiovascular Risk Factors (ASSERT-II). NCT01694394.
19. Reiffel J, Verma A, Halperin JL, et al. Rationale and design of REVEAL AF: a prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. Am Heart J 2014;167:22-7.
20. Rosero SZ, Kutyifa V, Olshansky B, et al. Ambulatory ECG monitoring in atrial fibrillation management. Prog Cardiovasc Dis 2013;56:143-52.
21. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014;13:429-38.
22. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467-77.
23. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478-86.
24. Colivicchi F, Bassi A, Santini M, et al. Prognostic implications of right-sided insular damage, cardiac autonomic derangement, and arrhythmias after acute ischemic stroke. Stroke 2005;36:1710-15.
25. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003;107:1614-19.
26. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009;2:474-80.
27. Shanmugam N, Boerdlein A, Proff J, et al. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 2012;14:230-7.
28. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-9.
29. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014;35:508-16.
30. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129:2094-9.
31. Engdahl J, Andersson L, Mirskaya M, et al. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013;127:930-7.
32. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013;2:e000102.
33. Brunner KJ, Bunch TJ, Mullin CM, et al. Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring. Mayo Clin Proc 2014;89:1498-505.
34. Turakhia M. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). Clin Cardiol Published Online First: 14 Apr 2015.
35. Healy J. Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor-ClinicalTrials.gov. 2015.
36. Shibazaki K, Kimura K, Fujii S, et al. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol 2012;109:1303-7.
37. Beaulieu-Boire I, Leblanc N, Berger L, et al. Troponin elevation predicts atrial fibrillation in patients with stroke or transient ischemic attack. J Stroke Cerebrovasc Dis 2013;22:978-83.
38. Magnani JW, Johnson VM, Sullivan LM, et al. P wave duration and risk of longitudinal atrial fibrillation in persons >/=60 years old (from the Framingham Heart Study). Am J Cardiol 2011;107:917-21.e1.
39. Folkeringa RJ, Hartgers J, Tieleman RG, et al. Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy. Heart 2006;92:545-6.
40. Abhayaratna WP, Fatema K, Barnes ME, et al. Left atrial reservoir function as a potent marker for first atrial fibrillation or flutter in persons > or=65 years of age. Am J Cardiol 2008;101:1626-9.
41. Wong JM, Welles CC, Azarbal F, et al. Relation of left atrial dysfunction to ischemic stroke in patients with coronary heart disease (from the heart and soul study). Am J Cardiol 2014;113:1679-84.
42. National Collaborating Centre for Chronic C, National Institute for Health and Clinical Excellence: Guidance. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians (UK), 2006.
43. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-61.
44. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281-7a. England: Published on behalf of the European Society of Cardiology The Author 2014. For permissions please email: journals.permissions@oup.com.
45. Healey J. Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation ClinicalTrials.gov Identifier: NCT01938248.
46. Friberg L, Engdahl J, Frykman V, et al. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 2013;15:135-40.
47. Chicos A. Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT COM). ClinicalTrials.gov identifier: NCT01706146 (accessed 28 Feb 2015).
48. Zimetbaum P. Pilot Study: Tailored Anticoagulation for Noncontinuous AF. ClinicalTrials.gov identifier: NCT01650298.
49. Ip J, Waldo AL, Lip GY, et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J 2009;158:364-70.e1.
50. Chen-Scarabelli C, Scarabelli TM, Ellenbogen KA, et al. Device-detected atrial fibrillation: what to do with asymptomatic patients? J Am Coll Cardiol 2015;65:281-94.